Close Monitoring, Full-Time Caregiver Recommended for 30 Days After CAR-T Therapy
Readmissions for CRS, neurotoxicity, infection, and other adverse events are common after immunotherapy with axicabtagene ciloleucel.
ASCO 2020
Palliative Care in Phase 1 Trials is Essential for Patients and Their Caregivers
Structured palliative care can ensure these patients and their caregivers have an optimal experience that does not hinder trial outcomes.
ASCO: Drop in Cancer Mortality Greater With Medicaid Expansion
Estimated 785 fewer cancer deaths in 2017 in states that expanded Medicaid.
Immune-Oncology Education Improved Patient Self-Efficacy
A patient education and monitoring program improved patients’ ability to manage and report adverse events related to treatment with ICIs.
Hemophagocytic Lymphohistiocytosis and CAR-T Cell Therapy
Progression-free and overall survival were worse among patients with HLH receiving CAR-T cell therapy by 10-month follow-up.
Untreated Follicular Lymphoma: Obinutuzumab vs Rituximab Efficacy, Safety in Combination With Chemotherapy
Obinutuzumab plus chemotherapy showed more durable efficacy, safety, and longer progression-free survival for patients with untreated follicular lymphoma.
Fixed-Duration Venetoclax-Obinutuzumab for Untreated Chronic Lymphocytic Leukemia
Promising follow-up data on safety and efficacy of fixed-duration venetoclax-obinutuzumab for patients with untreated CLL.
Treatment With Hydroxychloroquine-Azithromycin, Progressive Cancer Found to Increase Risk of Death for Patients With COVID-19
Only 2 patients received hydroxychloroquine as part of a clinical trial, and about 10% were taking the drug at the time of their COVID-19 presentation.
KRd Fails to Improve Outcomes Compared With VRd in Newly Diagnosed MM
Carfilzomib plus lenalidomide and dexamethasone failed to improve outcomes compared with bortezomib plus lenalidomide and dexamethasone among patients with newly-diagnosed MM.
C difficile Infection May Increase Graft vs Host Disease Risk
Patients undergoing allogeneic stem cell transplantation who experience C difficile infections may have an increased risk for graft vs host disease.
- Loading...
Loading...
Next post in ASCO 2020
Loading... 
Loading...